2415659-01-5
2415659-01-5 structure
- Name: Nicotinamide riboside malate
- Chemical Name: Nicotinamide riboside malate
- CAS Number: 2415659-01-5
- Molecular Formula: C15H20N2O10
- Molecular Weight: 388.33
- Catalog: Signaling Pathways Cell Cycle/DNA Damage Sirtuin
- Create Date: 2020-08-08 12:09:33
- Modify Date: 2024-01-03 17:14:06
-
Nicotinamide riboside malate, an orally active NAD+ precursor, increases NAD+ levels and activates SIRT1 and SIRT3. Nicotinamide riboside malate is a source of vitamin B3 (niacin) and enhances oxidative metabolism, protection against high fat diet-induced metabolic abnormalities[1]. Nicotinamide riboside malate reduces cognitive deterioration in a transgenic mouse model of Alzheimer’s disease[2].
| Name | Nicotinamide riboside malate |
|---|
| Description | Nicotinamide riboside malate, an orally active NAD+ precursor, increases NAD+ levels and activates SIRT1 and SIRT3. Nicotinamide riboside malate is a source of vitamin B3 (niacin) and enhances oxidative metabolism, protection against high fat diet-induced metabolic abnormalities[1]. Nicotinamide riboside malate reduces cognitive deterioration in a transgenic mouse model of Alzheimer’s disease[2]. |
|---|---|
| Related Catalog | |
| Target |
SIRT1 SIRT3 |
| In Vitro | Nicotinamide riboside malate (0.5 nM; 24 hours) reduces the acetylation status of Ndufa9 and SOD2[1]. Nicotinamide riboside malate increases intracellular and mitochondrial NAD+ content in C2C12, Hepa1.6, and HEK293 cells in a concentration-dependent manner at concentrations ranging from 1-1000 μM[1]. Nicotinamide riboside malate boosts NAD to restore antiviral poly(ADP-ribose) polymerase (PARP) functions to support innate immunity for coronavirus (CoVs), a cause of COVID-19[3]. Western Blot Analysis[1] Cell Line: HEK293T cells Concentration: 0.5 nM Incubation Time: 24 hours Result: Reduced the acetylation status of Ndufa9 and SOD2. |
| In Vivo | Chronic Nicotinamide riboside malate (p.o.; 400 mg/kg/day; for 16 weeks) supplementation increases plasma and intracellular NAD+ content in a tissue-specific manner[1]. Animal Model: 10-week-old C57Bl/6J mice[1] Dosage: 400 mg/kg Administration: PO; daily; for 16 weeks Result: Increased plasma and intracellular NAD+ content in a tissue-specific manner. |
| References |
| Molecular Formula | C15H20N2O10 |
|---|---|
| Molecular Weight | 388.33 |